Evidence for the use of intravenous immunoglobulins - A review of the literature

Shaye Kivity, Uriel Katz, Natalie Daniel, Udi Nussinovitch, Neophytos Papageorgiou, Yehuda Shoenfeld*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies. In 1981, Paul Imbach noticed an improvement of immune-mediated thrombocytopenia, in patients receiving IVIg for immunodeficiencies. This opened a new era for the treatment of autoimmune conditions with IVIg. Since then, IVIg has become an important treatment option in a wide spectrum of diseases, including autoimmune and acute inflammatory conditions, most of them off-label (not included in the US Food and Drug Administration recommendation). A panel of immunologists and internists with experience in IVIg therapy reviewed the medical literature for published data concerning treatment with IVIg. The quality of evidence was assessed, and a summary of the available relevant literature in each disease was given. To our knowledge, this is the first all-inclusive comprehensive review, developed to assist the clinician when considering the use of IVIg in autoimmune diseases, immune deficiencies, and other conditions.

Original languageEnglish
Pages (from-to)201-269
Number of pages69
JournalClinical Reviews in Allergy and Immunology
Issue number2-3
StatePublished - Apr 2010


  • Autoimmunity
  • Evidence
  • IVIg
  • IgIV
  • Intravenous gamma globulins
  • Intravenous immunoglobulins


Dive into the research topics of 'Evidence for the use of intravenous immunoglobulins - A review of the literature'. Together they form a unique fingerprint.

Cite this